Home> Industry News > All

Alexion’s rare blood disorder treatment ALXN121 succeeds in phase 3 study

clinical trialsAlexion Pharmaceuticals2018-03-19 08:24Read   91

Alexion Pharmaceuticals' investigational long-acting C5 complement inhibitor, ALXN1210, has succeeded in the pivotal phase 3 study of patients with rare blood disorder, paroxysmal nocturnal hemoglobinuria (PNH).

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

TrendMerck2018-03-09 09:48Read   84

Merck & Co likes the data coming out of trials combining its immuno-oncology drug Keytruda with Eisai’s Lenvima - and has signed a big deal to bind the two products closer together.

Sanofi taps Evotec for new anti-infectives drive

TrendSanofi 2018-03-09 09:44Read   62

The duo will set up the initiative at Sanofi’s R&D unit in France

VBL Therapeutics sees Avastin-VB-111 phase 3 combo flop in brain cancer

TrendFierceBiotech2018-03-09 09:44Read   70

Israeli biotech VBL Therapeutics has joined a long and depressing line of companies that have failed to move the needle in a test against a form of aggressive brain tumor.

Novartis to use Science 37's technology in 10 clinical trials

clinical trialsNovartis 2018-03-09 09:39Read   113

Novartis said that it will use Science 37's Network Oriented Research Assistant (NORA) technology in up to 10 clinical trials over the next three years.

Best Way to Fight Off Norovirus: Wash Your Hands

TrendHealthDaqy2018-03-09 09:39Read   49

Washing your hands often and thoroughly is the best way to protect yourself if you're caught in a norovirus outbreak, researchers say.

CRISPR-based system identifies important new drug targets in a deadly leukaemia

R&DCold Spring Harbour 2018-03-09 09:39Read   50

Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered a way to rein in an overactive protein that drives some aggressive leukaemias.

Boehringer Ingelheim, Lilly expand heart failure program for Jardiance with new clinical trials

TrendBoehringer Ingelheim2018-03-09 08:26Read   35

Boehringer Ingelheim and Eli Lilly have unveiled plans to expand their clinical trial program for Jardiance in chronic heart failure with the EMPERIAL clinical trials.

Many clinical trial status discrepancies identified between ClinicalTrials.gov and EUCTR

Trendworldpharmanews2018-03-09 08:18Read   32

Approximately one sixth of clinical trials registered on both ClinicalTrials.gov and the EU Clinical Trials Register (EUCTR) have discrepancies in their completion status, according to a study published March 7, 2018 in the open-access journal PLOS ONE by Jessica Fleminger and Ben Goldacre from the University of Oxford, UK.

Cognitive decline prevalent among elderly patients with hematologic cancers, study finds

TrendDana-farber2018-03-07 09:08Read   38

A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning, a decline that may impact their survival, a new study by investigators at Dana-Farber Cancer Institute and Brigham and Women's Hospital (BWH) indicates.

Therapeutic value for the protein aryl hydrocarbon receptor

R&DUniversity of Extremadura2018-03-07 08:57Read   31

Cancer stem cells possess the capacity to adopt highly undifferentiated states, characteristic of pluripotent cells, which very possibly contribute to the progression and maintenance of the different cells that form the tumour, in the same way that a healthy stem cell can give rise to different cell phenotypes.

Dermira craters as acne drug fails late-stage test

TrendDermira 2018-03-07 08:56Read   33

The US biotech lost two-thirds of its share value after the news broke

First Prev 1 2 3 4 Next Last GO
You may interest
Insert title here
Feed-Back To Top
ICP Permit 14047345| Beijing PSB Hai Dian Record 11010802017043 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)
Insert title here
Feed-Back To Top